Multiple epithelioid spitz nevi or tumors with loss of BAP1 expression: A clue to a hereditary tumor syndrome

JAMA Dermatology

Volumn 149, Issue 3, 2013, Pages 335-339

  Busam, Klaus J ^a   Wanna, Michelle ^b   Wiesner, Thomas ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Avera Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN BAP1; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BAP1 GENE; BIOPSY; CASE REPORT; CONTROLLED STUDY; DNA SEQUENCE; FOOT DISEASE; FRAMESHIFT MUTATION; GENE; GENE LOCUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; JUVENILE MELANOMA; MALE; MELANOCYTIC NEVUS; NULL ALLELE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; SCALP NODULE; SKIN NODULE; SKIN PRURITUS; TOE LESION;

EPITHELIOID CELLS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GERM-LINE MUTATION; HUMANS; MALE; MELANOCYTES; NEVUS, EPITHELIOID AND SPINDLE CELL; SEQUENCE ANALYSIS, DNA; SKIN NEOPLASMS; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN THIOLESTERASE; YOUNG ADULT;

EID: 84875391417     PISSN: 21686068     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamadermatol.2013.1529     Document Type: Article

References (23)

1. Zedek DC, McCalmont TH. Spitz nevi, atypical spitzoid neoplasms, and spitzoid melanoma. Clin Lab Med. 2011;31(2):311-320.
2. Scolyer RA, Murali R, McCarthy SW, Thompson JF. Histologically ambiguous ("borderline") primary cutaneous melanocytic tumors: approaches to patient management including the roles of molecular testing and sentinel lymph node biopsy. Arch Pathol Lab Med. 2010;134(12):1770-1777.
3. Miteva M, Lazova R. Spitz nevus and atypical spitzoid neoplasm. Semin Cutan Med Surg. 2010;29(3):165-173.
4. Barnhill RL, Argenyi ZB, From L, et al. Atypical Spitz nevi/tumors: lack of consensus for diagnosis, discrimination from melanoma, and prediction of outcome. Hum Pathol. 1999;30(5):513-520.
5. Busam KJ, Murali R, Pulitzer M, et al. Atypical spitzoid melanocytic tumors with positive sentinel lymph nodes in children and teenagers, and comparison with histologically unambiguous and lethal melanomas. Am J Surg Pathol. 2009;33(9):1386-1395.
6. Wiesner T, Murali R, Fried I, et al. A distinct subset of atypical Spitz tumors is characterized by BRAF mutation and loss of BAP1 expression. Am J Surg Pathol. 2012;36(6):818-830.
7. Wiesner T, Obenauf AC, Murali R, et al. Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet. 2011;43(10):1018-1021.
8. Bastian BC, LeBoit PE, Pinkel D. Mutations and copy number increase of HRAS in Spitz nevi with distinctive histopathological features. Am J Pathol. 2000;157(3):967-972.
9. Bastian BC, Wesselmann U, Pinkel D, Leboit PE. Molecular cytogenetic analysis of Spitz nevi shows clear differences to melanoma. J Invest Dermatol. 1999;113(6):1065-1069.
10. Palmedo G, Hantschke M, Rütten A, et al. The T1796A mutation of the BRAF gene is absent in Spitz nevi. J Cutan Pathol. 2004;31(3):266-270.
11. Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet. 2003;33(1):19-20.
12. Si L, Kong Y, Xu X, et al. Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort. Eur J Cancer. 2012;48(1):94-100.
13. Yoshikawa Y, Sato A, Tsujimura T, et al. Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma. Cancer Sci. 2012;103(5):868-874.
14. Testa JR, Cheung M, Pei J, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet. 2011;43(10):1022-1025.
15. Bott M, Brevet M, Taylor BS, et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet. 2011;43(7):668-672.
16. Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2006;24(26):4340-4346.
17. Carvajal RD, Antonescu CR, Wolchok JD, et al. KIT as a therapeutic target in metastatic melanoma. JAMA. 2011;305(22):2327-2334.
18. van Engen-van Grunsven AC, van Dijk MC, Ruiter DJ, Klaasen A, Mooi WJ, Blokx WA. HRAS-mutated Spitz tumors: a subtype of Spitz tumors with distinct features. Am J Surg Pathol. 2010;34(10):1436-1441.
19. Van Raamsdonk CD, Bezrookove V, Green G, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature. 2009;457(7229):599- 602.
20. Van Raamsdonk CD, Griewank KG, Crosby MB, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med. 2010;363(23):2191-2199.
21. Abdel-Rahman MH, Pilarski R, Cebulla CM, et al. Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J Med Genet. 2011;48(12):856-859.
22. Harbour JW, Onken MD, Roberson ED, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science. 2010;330(6009):1410-1413.
23. Njauw CN, Kim I, Piris A, et al. Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families. PLoS One. 2012;7(4):e35295. http://www.ncbi.nlm.nih.gov/pmc/ articles/PMC3335872/. Accessed January 11, 2013.